The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events

Aberrant activities of various cell cycle and DNA repair proteins promote cancer growth and progression and render them resistant to therapies. Here, we demonstrate that the anti-depressant imipramine blocks growth of triple-negative (TNBC) and estrogen receptor-positive (ER+) breast cancers by inducing cell cycle arrest and by blocking heightened homologous recombination (HR) and non-homologous end joining-mediated (NHEJ) DNA repair activities. Our results reveal that imipramine inhibits the expression of several cell cycle-and DNA repair associated proteins including E2F1, CDK1, Cyclin D1, and RAD51. In addition, we show that imipramine inhibits the growth of ER + breast cancers by inhibiting the estrogen receptor-alpha (ER-alpha) signaling. Our studies in pre clinical mouse models and ex vivo explants from breast cancer patients show that imipramine sensitizes TNBC to the PARP inhibitor olaparib and endocrine resistant ER + breast cancer to anti-estrogens. Our studies suggest that repurposing imipramine could enhance routine care for breast cancer patients. Based on these results, we designed an ongoing clinical trial, where we are testing the efficacy of imipramine for treating patients with triple-negative and estrogen receptor-positive breast cancer. Since aberrant DNA repair activity is used by many cancers to survive and become resistant to therapy, imipramine could be used alone and/or with currently used drugs for treating many aggressive cancers.

Automated summary

The anti-depressant imipramine can block the growth of breast cancer by inducing cell cycle arrest and inhibiting DNA repair activities. Imipramine inhibits the expression of cell cycle and DNA repair associated proteins and also inhibits estrogen receptor signaling. It can enhance the sensitivity of triple-negative breast cancer to PARP inhibitors and endocrine resistant breast cancer to anti-estrogens.